Reproductive & Sexual Health Peptides

Different biological pathways

Bremelanotide acts through melanocortin receptors. Kisspeptin participates in reproductive hormonal signaling and is being investigated for effects on sexual processing. Their mechanisms and evidence differ.

Bremelanotide and its indication

The US Vyleesi label describes acquired, generalized hypoactive sexual desire disorder in premenopausal women under specific diagnostic criteria. It is not a general sexual-performance enhancer. Egyptian product registration and availability remain unverified here.

Kisspeptin studies

A randomized crossover trial in women with low desire studied short-term brain responses and related measures after kisspeptin exposure. Such findings help design further trials. They do not establish routine long-term treatment effectiveness.

Evidence and practical meaning

A change on functional imaging is an intermediate outcome. Longer studies should assess symptoms that matter to patients, sustained benefit, adverse effects and appropriate candidates.

Safety and contraindications

Bremelanotide can cause nausea and transient blood-pressure increases. Its US label contraindicates use with uncontrolled hypertension or known cardiovascular disease. Product-specific counseling and a medical assessment are essential.

Confidential, whole-person assessment

Sexual symptoms can relate to medicines, mood, pain, relationship context and hormonal conditions. A private consultation can identify appropriate investigations and referral without presuming a medication is needed.

Regulatory context in Egypt

Authorization belongs to an exact medicine, formulation, route and indication. Egyptian registration and the clinical governance of any future REVIVE service must be verified individually. A reference to overseas research or authorization does not establish local availability.

Frequently asked questions